Formic Acid

Formic Acid

SCHEMBL582126

N.N.N.N.N.N.O=CO.O=CO.O=CO.O=CO.O=CO.O=CO.O=CO

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.33
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL2303 1.00
Formic Acid SCHEMBL83909 1.00
Formic Acid SCHEMBL1064783 1.00
Formic Acid SCHEMBL2511100 1.00 ALDH1A1 (0.33) ALDH1A1TSHR
Formic Acid SCHEMBL1545886 1.00 ALDH1A1 (0.33) ALDH1A1TSHR
Formic Acid SCHEMBL811681 1.00
Formic Acid SCHEMBL394887 1.00 ALDH1A1 (0.33) ALDH1A1TSHR
Formic Acid SCHEMBL1545869 1.00 ALDH1A1 (0.33) ALDH1A1TSHR
Formic Acid SCHEMBL18112628 1.00 ALDH1A1 (0.33) ALDH1A1TSHR
Formic Acid SCHEMBL8503775 1.00

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9896422-B2 Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits Neumedics (US) 2018-02-20 US disclosed
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. 2017-12-07 US disclosed
US-9815770-B2 Inhibitors of cognitive decline COGNITION THERAPEUTICS, INC. (US) 2017-11-14 US disclosed
EP-2670402-B1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS INC (US) 2017-09-20 EP disclosed
US-20170197977-A9 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE COGNITION THERAPEUTICS, INC. (US) 2017-07-13 US disclosed
US-20170144979-A1 TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS Neumedics (US) 2017-05-25 US disclosed
US-20170049723-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE COGNITION THERAPEUTICS, INC. 2017-02-23 US disclosed
US-9573912-B2 Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits Neumedics (US) 2017-02-21 US disclosed
US-20160355458-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. 2016-12-08 US disclosed
US-9499462-B2 Isolated compounds from turmeric oil and methods of use COGNITION THERAPEUTICS, INC. (US) 2016-11-22 US disclosed
EP-2458983-A1 INHIBITORS OF COGNITIVE DECLINE Cognition Therapeutics, Inc. (US) 2012-06-06 EP disclosed
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-05-24 US disclosed
US-20120095105-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2012-04-19 US disclosed
EP-2416795-A1 Inhibitors of cognitive decline Cognition Therapeutics, Inc. (US) 2012-02-15 EP disclosed
EP-2307027-A1 TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS Neumedics (US) 2011-04-13 EP disclosed
WO-2011014880-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2011-02-03 WO disclosed
WO-2010118055-A1 INHIBITORS OF COGNITIVE DECLINE COGNITION THERAPEUTICS, INC. (US) 2010-10-14 WO disclosed
US-20100087392-A1 COMPLEXES OF IBUPROFEN, CYCLODEXTRINS AND TERNARY AGENTS AND THE USE THEREOF IN PHARMACEUTICS PIERRE FABRE MEDICAMENT (FR) 2010-04-08 US disclosed
WO-2010006292-A1 TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS Neumedics (US) 2010-01-14 WO disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349554-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, SIGMAR1 ALDH1A1 4387/4885TSHR 2498/4885
US-20120095105-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R ALDH1A1 4542/4885TSHR 187/4885
US-20120129945-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885
US-20160355458-A1 INHIBITORS OF COGNITIVE DECLINE PSEN2, ACHE, MAPT ALDH1A1 3071/4885TSHR 4113/4885
US-20170049723-A1 ISOLATED COMPOUNDS FROM TURMERIC OIL AND METHODS OF USE APP, MAPT, PSEN1 ALDH1A1 3105/4885TSHR 4146/4885
US-20170197977-A9 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE TMEM97, SLC18A2, CHRNB2 ALDH1A1 3240/4885TSHR 3559/4885
US-20170144979-A1 TETRACYCLINE DERIVATIVES WITH REDUCED ANTIBIOTIC ACTIVITY AND NEUROPROTECTIVE BENEFITS DCX, CASP3, BCL2 ALDH1A1 4504/4885TSHR 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.